Catalent makes new appointment
Wetteny Joseph chosen to lead the company’s Clinical Supply Services Business.
Catalent Pharma Solutions has appointed Wetteny Joseph as its new President, Clinical Supply Services.
Mr Joseph first joined Catalent in 2008 as Corporate Controller, and in 2012, was charged with leading the finance function for the company’s Modified Release Technologies business unit. In 2013, Mr Joseph was promoted to Vice President of Finance for Catalent’s Development and Clinical Services division, which included the Clinical Supply Services business unit.
“I have the utmost confidence in Wetteny’s ability to lead our Clinical Supply Services business, in which we have invested significantly over the last few years,” commented Catalent CEO and President, John Chiminski. He added: “Wetteny’s expert contribution to the 2012 acquisition of Aptuit, and more recent major capacity and capability upgrades, have strengthened our global reach in Asia Pacific, increased our overall capacity, and broadened our service offering in the clinical services market.”
Before joining Catalent, Mr Joseph held senior financial positions at HD Supply, including CFO of a $1.2 billion business unit. He also served as Corporate Controller at Hughes Supply, a Fortune 500 company. In his early career, Mr Joseph spent 6 years at PricewaterhouseCoopers as an auditor, and as a strategic financial advisor across a variety of industries.
Mr Joseph earned both his master’s and bachelor’s degrees in accounting from Florida Atlantic University.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.